Novartis logo

Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Antwerp terminal

Health & Healthcare | Novartis

Energize – A First-of-Its-Kind Program to Increase Access to Renewable Energy for Pharmaceutical Suppliers

The Energize program is a collaboration between 10 global pharmaceutical companies, including Novartis, to engage hundreds of suppliers in bold climate action and decarbonization of the pharmaceutical value chain.

Flexible Media Releases

Energize – A First-of-Its-Kind Program to Increase Access to Renewable Energy for Pharmaceutical Suppliers

Novartis and Medicines for Malaria Venture Report Positive Results for Phase 2b Study of Novel Ganaplacide/Lumefantrine Combination in Children With Malaria

Together Against Child Mortality: Novartis and Save the Children Launch Health Project in the Slums of Nairobi

Novartis Pledges 10-year Commitment With Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and Other Leading Organizations to Co-create Effective, Measurable Solutions for Health Equity

Novartis and Hewlett Packard Enterprise Join Forces to Advance Novartis Global Health Efforts

Novartis Reaches Milestone Delivery of 1 Billion Courses of Antimalarial Treatment

Novartis Inaugurates Innovative Watershed Project in India to Increase Water Availability

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Novartis in Society US Report 2020

Novartis Renews WHO Medicine Donation Pledge With Aim of Ending Leprosy

Novartis and GSK Announce Collaboration to Support Scientific Research Into Genetic Diversity in Africa

Novartis Set to Achieve 100% Renewable Electricity in Its European Operations

Contact Tracing With Prophylactic Treatment Could Near-Eliminate Leprosy in a Single Generation, New Research Suggests

OLON Continues Strategic Collaboration With Novartis, Supporting the Expansion of the Africa Sickle Cell Disease Program to Kenya, Uganda and Tanzania

Life Science Companies and the Bill & Melinda Gates Foundation: Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines

Campaigns

Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

Novartis US Foundation
Initiatives summarizing efforts from the Novartis US Foundation.

Novartis COVID-19 Trials
Novartis clinical trial efforts in COVID-19 R&D.

Novartis US Foundation COVID-19 Response
In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

Novartis – science based innovation for better patient outcomes
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novartis Foundation Leprosy Elimination Initiative
The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

Novartis Access: Medicines to treat chronic diseases in lower-income countries
Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

The Novartis Malaria Initiative
For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...

Videos

Contact Novartis
email
corporate.responsibility@novartis.com
open_in_new
Learn more about corporate responsibility at Novartis
open_in_new
Novartis Foundation